Slingshot members are tracking this event:
Data Released From Dermira's (DERM) Phase 2b Study of Lebrikizumab in Patients With Atopic Dermatitis at Fall Clinical Dermatology Conference
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
The primary endpoint of the study was the percent change in EASI from baseline to week 16. Secondary endpoints that were evaluated during the 16-week treatment period included: the proportion of patients with a 75 percent improvement from baseline in EASI score (EASI-75); the proportion of patients with a reduction of 2 or more points in IGA score from baseline to a final score of 0 (clear) or 1 (almost clear) (IGA0/1); the proportion of patients achieving EASI-50 and EASI-90; changes in pruritus (itch) and sleep loss scores from baseline, each scored using a numerical rating scale (NRS); and the proportion of patients with an improvement in pruritus NRS score (on an 11-point scale) of at least 4 points from baseline.
Slingshot Insights Explained
Oct 17, 2019
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 2b, Lebrikizumab, Atopic Dermatitis